Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXKOUC)

Drug Name
Neu-120 Drug Info
Synonyms Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMXKOUC

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Modulator [2]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glycogen synthase kinase-3 beta (GSK-3B) DTT GSK3B 6.506 6.618 6.514 6.885
Monoamine oxidase type B (MAO-B) DTT MAOB 9.367 6.907 8.237 8.409
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glycogen synthase kinase-3 beta (GSK-3B) DTT GSK3B 1.26E-01 -0.23 -0.77
Monoamine oxidase type B (MAO-B) DTT MAOB 9.83E-01 0.04 0.19
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00607451) Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia. U.S. National Institutes of Health.
2 Company report (Neurim Pharmaceuticals)